Announced Sat, 30 May · 18:31 IST

This is to inform you that pursuant to Regulation 30 & Regulation 33 of Securities Exchange Board of India (Listing Obligation and Disclosure requirement) Regulation 2015 'Listing regulation' ....

Revenue Growth 20pctResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+10.8%1-day move
₹36.61
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+10.8+3.1+9.2+4.4+6.8+2.2-0.7+6.3
Up moveDown movePending
AI summary

Pentokey Organy India Ltd reported audited financial results for FY2026. Revenue from operations surged to Rs 209 lakh from Rs 82.62 lakh in the previous year, representing over 150% growth driven by the Pharma/Pesticides trading segment. However, profit before tax declined to Rs 20.32 lakh from Rs 24.55 lakh in FY2025, indicating margin compression despite strong revenue growth. The Q4 quarter showed a loss of Rs 13.14 lakh on negative revenue of Rs 186.39 lakh, though this appears to be a balancing figure. Statutory auditors M/s Verma Mehta & Associates issued an unmodified opinion, confirming clean financial statements with no material concerns. The company also received a favourable income tax order for AY 2015-16.

Likely market impact

Revenue growth is impressive but declining profitability despite higher sales raises concerns about cost efficiency. The clean audit opinion and positive operating cash flow of Rs 75.66 lakh provide some comfort to shareholders.